Koch Disruptive Technologies has provided $110m for the drug discovery technology startup's series B round following a $190m first close in January.
Valo Health, a US-based developer of drug discovery technology, closed its series B round at $300m yesterday with $110m from Koch Disruptive Technologies, a subsidiary of chemicals and industrial group Koch Industries.
The $190m first close was led by Canadian pension fund manager Public Sector Pension Investment Board (PSP Investments) in January this year and included Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment and Mirae Asset Capital.
Founded in 2019, Valo leverages machine learning technology and human-focused…
